- Home
- FBRX vs PCN Comparison
FBRX vs PCN Comparison
Compare FBRX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | PCN |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.4M | 881.0M |
| IPO Year | 2017 | 2001 |
Fundamental Metrics
Financial Performance| Metric | FBRX | PCN |
|---|---|---|
| Price | $51.24 | $11.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 824.3K | 306.4K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.25 | $11.40 |
| 52 Week High | $52.15 | $13.49 |
Technical Indicators
Market Signals| Indicator | FBRX | PCN |
|---|---|---|
| Relative Strength Index (RSI) | 84.70 | 48.05 |
| Support Level | $24.72 | $11.60 |
| Resistance Level | N/A | $12.09 |
| Average True Range (ATR) | 4.86 | 0.10 |
| MACD | 2.32 | -0.01 |
| Stochastic Oscillator | 96.65 | 36.05 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.